At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Esomeprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Proton Pump Inhibitors on CF Exacerbations
In Brief
A Phase 2 clinical trial evaluating Esomeprazole and Placebo for Cystic Fibrosis. Completed, enrolled 21 participants across 1 site.
Detailed Summary
Gastroesophageal reflux disease (GERD) is a common problem in cystic fibrosis (CF). It may lead to worsening lung function and more respiratory infections for a person with CF. This study will look at treating GERD with a medication, esomeprazole. The medication stops stomach acid from being made. The study will see if there are fewer respiratory infections and improved lung function in patients with CF when taking esomeprazole.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
Primary CompletionAug 2011
First PostedNov 2013
TodayJul 2026
First PostedNov 14, 2013
Enrollment StartFeb 1, 2008
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.6 years ago
Interventions
Esomeprazoledrug
Placebodrug
Sugar pill